Showing results (91-100 of 146) with videos related to
Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2024
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus VenetoclaxAlexandre Bazinet, Sai Prasad Desikan, Ziyi Li, et al.The Lancet. Haematology|February 5, 2024
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 studyAlex Bataller, Guillermo Montalban-Bravo, Alexandre Bazinet, et al.Journal of Hematology & Oncology|January 30, 2022
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposureNicholas J Short, Sangeetha Venugopal, Wei Qiao, et al.Blood Advances|November 2, 2022
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AMLGhayas C Issa, Aram Bidikian, Sangeetha Venugopal, et al.JCO Oncology Practice|July 16, 2024
Outcomes of Patients With Newly Diagnosed AML and HyperleukocytosisFadi G Haddad, Koji Sasaki, Jayastu Senapati, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|March 6, 2004
Effects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failureMatthias Schmitt, Prasad Gunaruwan, Nicola Payne, et al.Blood Neoplasia|June 2, 2025
Adult leukemia in Florida 2010-2019: diverse, aging population as an indicator for the United StatesMing S Lee, Rebecca E Kaiser, Christopher D Armstrong, et al.Blood Advances|August 16, 2022
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndromeCourtney D DiNardo, Sangeetha Venugopal, Curtis Lachowiez, et al.NPJ Precision Oncology|July 2, 2025
Functional cure with single agent olutasidenib in relapsed IDH1/NPM1 co-mutated AMLJustin Watts, Tiffany Nong, Katarina Micin, et al.Nature Reviews. Clinical Oncology|November 2, 2024
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemiaMichele D Stanchina, Skye Montoya, Alexey V Danilov, et al.Pageof 15